Navigation Links
Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
Date:9/22/2013

ctivity, therapeutic potential and safety of ISIS-APOCIIIRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... -- The spinal column is one of the most delicate ... and from the brain through the column control many key ... ailment here can be life altering, and leave the victim ... their body. Though back injury and disease can have an ... options available to make things better than ever before. ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... MOSCOW, Nov. 16, 2011 The Nutrilite Health Institute ... a U.S.-Russia collaboration demonstrating that overweight Russian adults have ... may be linked to poor long-term health outcomes. The ... extend beyond the initial findings presented in late 2010 ...
... Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and ... to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ... year, we introduced and began marketing the Aethlon ADAPT™ ... and drug world to establish a new class of ...
Cached Medicine Technology:Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 2Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 3Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 4Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4Aethlon Medical Releases Shareholder Letter 5Aethlon Medical Releases Shareholder Letter 6Aethlon Medical Releases Shareholder Letter 7
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide and ... from legally blind to perfect 20/20 vision has caught the ... “There is a huge portion of the population today that ... people just think that’s the way it will always be ... pretty risky at times,” reports Michaels. “This program is a ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... DENVER For the first time an oncogenic somatic ... during transfection) protein has been identified in small cell ... mutation within SCLC cell lines produced increased intracellular signaling ... form of lung cancer representing 15% of all lung ... representing 85% of lung cancer, has been extensively examined ...
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... in two years, California researcher says , , FRIDAY, Feb. 1 ... the progress of the disease in 90 percent of the ... turned the cancer into a chronic, manageable disease," said W. ... Feb. 1 issue of Cancer Research . , Twenty ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... 1 Lifespring Health,sponsors the Kaiser Permanente San Francisco ... charity event benefiting the Hemophilia Foundation of,Northern California, Support ... House., Set to take place on Feb. 3, ... course is ranked as one of the most scenic,in ...
... Piwek to Assist in Generating New Retail Licensing ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), a ... patented dermatology,products with their proprietary polymer delivery system ... selected as a new member of,the Company,s Board ...
... and vigilance show a relationship with core body temperature ... high during the daytime, skin temperature is low, which ... temperature is low at night time, skin temperature is ... suffering from narcolepsy, however, direct manipulations of their skin ...
... , UCLA and University of North Carolina researchers have found ... sexual and/or physical abuse may have a heightened brain response ... IBS is a condition that affects 10 to 15 percent ... constipation or both. , Researchers used brain ...
Cached Medicine News:Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
... Introducing the new PRONEB® ULTRA compressor. This ... time while delivering more medication to the ... LC PLUS® or PARI LC STAR® Reusable ... optimized for inhalation and retention into the ...
... PRONEB® ULTRA compressor. This high output compressor ... more medication to the patient's lungs. When ... PARI LC STAR® Reusable Nebulizer, the particle ... and retention into the lungs. With less ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
... Air., ,Allied Healthcares Timeter® PCS 414 portable ... air compressors that you may wonder if its ... 414 features a durable, mar-resistant steel case thats ... weighs only 26.5 pounds. The PCS 414 has ...
Medicine Products: